1 active not recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow CNV: new trials by email Literature Review of CNV trials Research Report on CNV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD ABBV-RGX-314, Ranibizumab (LUCENTIS®) - AMD, nAMD | Phase 2 / Phase 3 | Active not recruiting | AbbVie | 671 | 2020-12-29 | 2026-04-28 |
Choroidal Neovascularization (1) · Eye Diseases (1) · Macular Degeneration (1) · Retinal Degeneration (1) · Retinal Diseases (1) · Wet Macular Degeneration (1)
Choroid Diseases (1) · Eye Diseases, Hereditary (1) · Metaplasia (1) · Neovascularization, Pathologic (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Uveal Diseases (1)
Ranibizumab (1)
AbbVie (1)
United States (1)